News
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy
The FDA said it needs more information before it can approve Regenxbio's gene therapy for Hunter syndrome, in a devastating decision for patients.
News
Lupin settles Myrbetriq patent spat with Astellas for $90m
Lupin will be able to keep its generic of Astellas' overactive bladder therapy Myrbetriq on the US market, after reaching a settlement agreement.
News
Novo Nordisk rises as Hims & Hers backs down on oral GLP-1
Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.
Sales & Marketing
Four reasons pharma is sweeping the Super Bowl despite FDA f...
The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?
News
Leqembi starts to deliver for Eisai and Biogen
Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
